Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 5/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.50 |
| ▸ | HTR3B | O95264 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.50 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.50 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 3/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2314419 | 1.00 | GRIN2B (0.54) | GRIN2BCES2CES1HTR3EHTR3B | |
| SCHEMBL14726663 | 1.00 | GRIN2B (0.54) | GRIN2BCES2CES1HTR3EHTR3B | |
| SCHEMBL3046778 | 0.89 | LMNA (0.55) | GRIN2BCES2CES1HTR3EHTR3B | |
| SCHEMBL3046775 | 0.89 | LMNA (0.55) | GRIN2BCES2CES1HTR3EHTR3B | |
| SCHEMBL2323978 | 0.83 | GAA (0.43) | GRIN2BPAX8KDM1ARAB9ANPC1 | |
| SCHEMBL15473285 | 0.83 | ESR1 (0.48) | GRIN2BHTR3EHTR3BPLAUHTR3A | |
| SCHEMBL2323974 | 0.83 | GAA (0.43) | GRIN2BPAX8KDM1ARAB9ANPC1 | |
| SCHEMBL21215222 | 0.81 | KDM1A (0.60) | KDM1ARAB9ANPC1GAA | |
| SCHEMBL2327864 | 0.80 | PDE2A (0.46) | GRIN2BKDM1ARAB9ANPC1GAA | |
| SCHEMBL2327867 | 0.80 | PDE2A (0.46) | GRIN2BKDM1ARAB9ANPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001870-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2026-01-01 | — | — | US | disclosed |
| EP-4363415-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2025-12-10 | — | — | EP | disclosed |
| EP-4634169-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | Pfizer Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-12448371-B2 | Inhibitor compounds | Cincera Therapeutics Pty Ltd (AU) | 2025-10-21 | — | — | US | disclosed |
| EP-4598908-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | Pfizer Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| EP-4228630-B1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | UNIV FREIBURG ALBERT LUDWIGS (DE) | 2025-03-05 | — | — | EP | disclosed |
| CN-119390664-A | Crystal form of compound containing alpha, beta unsaturated ketone and preparation method thereof | 山东大学 | 2025-02-07 | — | — | CN | disclosed |
| US-20240279217-A1 | Heterocyclic compounds for the treatment of tuberculosis | TECNIMEDE - Sociedade Técnico-medicinal, SA (PT) | 2024-08-22 | — | — | US | disclosed |
| US-20240277658-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2024-08-22 | — | — | US | disclosed |
| CN-114450281-B | Inhibitor compounds | 辛塞拉治疗私人有限公司 | 2024-08-16 | — | — | CN | disclosed |
| EP-1963289-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2008-09-03 | — | — | EP | disclosed |
| WO-2008073785-A2 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007079931-A1 | SUBSTITUTED OXADIAZOLE DERIVATIVES AND THEIR USE AS OPIOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2007-07-19 | — | — | WO | disclosed |
| US-7041685-B2 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-07-14 | — | — | US | disclosed |
| CN-1638776-A | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs | CYTOVIA INC (US) | 2005-07-13 | — | — | CN | disclosed |
| EP-1406632-A2 | SUBSTITUTED 3-ARYL-5-ARYL- 1,2,4]-OXADIAZOLES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030069276-A1 | Amino piperidine derivatives | F.HOFFMANN-LA ROCHE AG (CH) | 2003-04-10 | — | — | US | disclosed |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2003-03-06 | — | — | US | disclosed |
| WO-2002100826-A2 | SUBSTITUTED 3-ARYL-5-ARYL-[1,2,4]-OXADIAZOLES AND ANALOGS | CYTOVIA, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279217-A1 | Heterocyclic compounds for the treatment of tuberculosis | SDHA, NQO1, FNTB | GRIN2B 4775/4885CES2 1983/4885CES1 1255/4885 |
| US-20030069276-A1 | Amino piperidine derivatives | CCR5, CCR2, CXCR4 | GRIN2B 854/4885CES2 1673/4885CES1 3586/4885 |
| US-20260001870-A1 | INHIBITOR COMPOUNDS | CES1, NCEH1, NR1H2 | GRIN2B 2778/4885CES2 256/4885CES1 1/4885 |
| US-20030045546-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, API5 | GRIN2B 4583/4885CES2 3539/4885CES1 1908/4885 |
| US-12448371-B2 | Inhibitor compounds | SERPINB1, MMP1, SSB | GRIN2B 4664/4885CES2 1184/4885CES1 79/4885 |
| US-20240277658-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | GRIN2B 3214/4885CES2 3919/4885CES1 2270/4885 |
| US-20050154012-A1 | Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, CASP4 | GRIN2B 4563/4885CES2 3820/4885CES1 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.